BIORESTORATIVE THERAPIES INC (BRTX) Stock Price, Quote, News and Overview
NASDAQ:BRTX - Nasdaq - US0906556065 - Common Stock - Currency: USD
BRTX Quote, Performance and Key Statistics
NASDAQ:BRTX (4/17/2025, 8:04:48 PM)
1.75
+0.02 (+1.17%)
The current stock price of BRTX is 1.75 USD. In the past month the price increased by 2.34%. In the past year, price increased by 27.74%.
BRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About BRTX
Company Profile
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 11 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The company has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The firm has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
Company Info
BIORESTORATIVE THERAPIES INC
40 Marcus Drive
Melville NEW YORK US
CEO: Lance Alstodt
Employees: 11
Company Website: https://www.biorestorative.com/
Investor Relations: http://www.biorestorative.com/ir/
Phone: 16317608100
BIORESTORATIVE THERAPIES INC / BRTX FAQ
What is the stock price of BIORESTORATIVE THERAPIES INC today?
The current stock price of BRTX is 1.75 USD. The price increased by 1.17% in the last trading session.
What is the ticker symbol for BIORESTORATIVE THERAPIES INC stock?
The exchange symbol of BIORESTORATIVE THERAPIES INC is BRTX and it is listed on the Nasdaq exchange.
On which exchange is BRTX stock listed?
BRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIORESTORATIVE THERAPIES INC stock?
8 analysts have analysed BRTX and the average price target is 13.26 USD. This implies a price increase of 657.71% is expected in the next year compared to the current price of 1.75. Check the BIORESTORATIVE THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIORESTORATIVE THERAPIES INC worth?
BIORESTORATIVE THERAPIES INC (BRTX) has a market capitalization of 12.11M USD. This makes BRTX a Nano Cap stock.
How many employees does BIORESTORATIVE THERAPIES INC have?
BIORESTORATIVE THERAPIES INC (BRTX) currently has 11 employees.
What are the support and resistance levels for BIORESTORATIVE THERAPIES INC (BRTX) stock?
BIORESTORATIVE THERAPIES INC (BRTX) has a support level at 1.69 and a resistance level at 1.76. Check the full technical report for a detailed analysis of BRTX support and resistance levels.
Is BIORESTORATIVE THERAPIES INC (BRTX) expected to grow?
The Revenue of BIORESTORATIVE THERAPIES INC (BRTX) is expected to grow by 158.1% in the next year. Check the estimates tab for more information on the BRTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIORESTORATIVE THERAPIES INC (BRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BRTX, evaluating the profitability, health, valuation and growth aspects
- BIORESTORATIVE THERAPIES INC (BRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIORESTORATIVE THERAPIES INC (BRTX) Sales and EPS estimates to see what analysts future expectations are.
- BIORESTORATIVE THERAPIES INC (BRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIORESTORATIVE THERAPIES INC (BRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIORESTORATIVE THERAPIES INC (BRTX) Stock Chart to make your own analysis
- BIORESTORATIVE THERAPIES INC (BRTX) Latest news and press-releases to stay up to date.
Does BIORESTORATIVE THERAPIES INC (BRTX) stock pay dividends?
BRTX does not pay a dividend.
When does BIORESTORATIVE THERAPIES INC (BRTX) report earnings?
BIORESTORATIVE THERAPIES INC (BRTX) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of BIORESTORATIVE THERAPIES INC (BRTX)?
BIORESTORATIVE THERAPIES INC (BRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).
What is the Short Interest ratio of BIORESTORATIVE THERAPIES INC (BRTX) stock?
The outstanding short interest for BIORESTORATIVE THERAPIES INC (BRTX) is 14.32% of its float. Check the ownership tab for more information on the BRTX short interest.
BRTX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BRTX. When comparing the yearly performance of all stocks, BRTX is one of the better performing stocks in the market, outperforming 84.73% of all stocks.
BRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BRTX. The financial health of BRTX is average, but there are quite some concerns on its profitability.
BRTX Financial Highlights
Over the last trailing twelve months BRTX reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 66.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.12% | ||
| ROE | -105.25% | ||
| Debt/Equity | 0 |
BRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BRTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -27.06% and a revenue growth 158.1% for BRTX